Cargando…

Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy

Despite several therapeutic advances, malignant melanoma still remains a fatal disease for which novel and long-term curative treatments are needed. The successful development of innovative therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose, several m...

Descripción completa

Detalles Bibliográficos
Autores principales: Barutello, Giuseppina, Rolih, Valeria, Arigoni, Maddalena, Tarone, Lidia, Conti, Laura, Quaglino, Elena, Buracco, Paolo, Cavallo, Federica, Riccardo, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877660/
https://www.ncbi.nlm.nih.gov/pubmed/29534457
http://dx.doi.org/10.3390/ijms19030799
_version_ 1783310743426301952
author Barutello, Giuseppina
Rolih, Valeria
Arigoni, Maddalena
Tarone, Lidia
Conti, Laura
Quaglino, Elena
Buracco, Paolo
Cavallo, Federica
Riccardo, Federica
author_facet Barutello, Giuseppina
Rolih, Valeria
Arigoni, Maddalena
Tarone, Lidia
Conti, Laura
Quaglino, Elena
Buracco, Paolo
Cavallo, Federica
Riccardo, Federica
author_sort Barutello, Giuseppina
collection PubMed
description Despite several therapeutic advances, malignant melanoma still remains a fatal disease for which novel and long-term curative treatments are needed. The successful development of innovative therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose, several mouse models holding the promise to provide insight into molecular biology and clinical behavior of melanoma have been generated. The most relevant ones and their contribution for the advancement of therapeutic approaches for the treatment of human melanoma patients will be here summarized. However, as models, mice do not recapitulate all the features of human melanoma, thus their strengths and weaknesses need to be carefully identified and considered for the translation of the results into the human clinics. In this panorama, the concept of comparative oncology acquires a priceless value. The revolutionary importance of spontaneous canine melanoma as a translational model for the pre-clinical investigation of melanoma progression and treatment will be here discussed, with a special consideration to the development of innovative immunotherapeutic approaches.
format Online
Article
Text
id pubmed-5877660
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58776602018-04-09 Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy Barutello, Giuseppina Rolih, Valeria Arigoni, Maddalena Tarone, Lidia Conti, Laura Quaglino, Elena Buracco, Paolo Cavallo, Federica Riccardo, Federica Int J Mol Sci Review Despite several therapeutic advances, malignant melanoma still remains a fatal disease for which novel and long-term curative treatments are needed. The successful development of innovative therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose, several mouse models holding the promise to provide insight into molecular biology and clinical behavior of melanoma have been generated. The most relevant ones and their contribution for the advancement of therapeutic approaches for the treatment of human melanoma patients will be here summarized. However, as models, mice do not recapitulate all the features of human melanoma, thus their strengths and weaknesses need to be carefully identified and considered for the translation of the results into the human clinics. In this panorama, the concept of comparative oncology acquires a priceless value. The revolutionary importance of spontaneous canine melanoma as a translational model for the pre-clinical investigation of melanoma progression and treatment will be here discussed, with a special consideration to the development of innovative immunotherapeutic approaches. MDPI 2018-03-10 /pmc/articles/PMC5877660/ /pubmed/29534457 http://dx.doi.org/10.3390/ijms19030799 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Barutello, Giuseppina
Rolih, Valeria
Arigoni, Maddalena
Tarone, Lidia
Conti, Laura
Quaglino, Elena
Buracco, Paolo
Cavallo, Federica
Riccardo, Federica
Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy
title Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy
title_full Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy
title_fullStr Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy
title_full_unstemmed Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy
title_short Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy
title_sort strengths and weaknesses of pre-clinical models for human melanoma treatment: dawn of dogs’ revolution for immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877660/
https://www.ncbi.nlm.nih.gov/pubmed/29534457
http://dx.doi.org/10.3390/ijms19030799
work_keys_str_mv AT barutellogiuseppina strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy
AT rolihvaleria strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy
AT arigonimaddalena strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy
AT taronelidia strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy
AT contilaura strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy
AT quaglinoelena strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy
AT buraccopaolo strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy
AT cavallofederica strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy
AT riccardofederica strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy